160 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B N/A
Article Searches
Novo Nordisk Continues Its Balancing Act https://www.fool.com/investing/2018/11/08/novo-nordisk-continues-its-balancing-act.aspx?source=iedfolrf0000001 Nov 08, 2018 - Growth on one hand, but declines on the other.
Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jørgensen on Q3 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4217252-novo-nordisk-s-nvo-ceo-lars-fruergaard-jorgensen-q3-2018-results-earnings-call-transcript?source=feed_sector_healthcare Nov 01, 2018 -
Novo Nordisk (NVO) Q3 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2018/11/01/novo-nordisk-as-nvo-q3-2018-earnings-conference-ca.aspx?source=iedfolrf0000001 Nov 01, 2018 - NVO earnings call for the period ending September 30, 2018.
PFE or NVO: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/327938/pfe-or-nvo-which-is-the-better-value-stock-right-now?cid=CS-ZC--327938 Oct 15, 2018 - PFE vs. NVO: Which Stock Is the Better Value Option?
Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff http://www.zacks.com/stock/news/323818/novo-nordisk-to-restructure-rd-unit-lay-off-400-staff?cid=CS-ZC-FT-323818 Sep 19, 2018 - Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.
Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus http://www.zacks.com/stock/news/317383/pharma-stock-roundup-nvo-q2-earnings-jnj-agn-azns-pipeline-updates-in-focus?cid=CS-ZC-FT-317383 Aug 10, 2018 - Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.
Lilly (LLY) Issues Update on Diabetes Drug Trulicity Label http://www.zacks.com/stock/news/312546/lilly-lly-issues-update-on-diabetes-drug-trulicity-label?cid=CS-ZC-FT-312546 Jul 20, 2018 - Lilly (LLY) updates Trulicity's label to include data from a new study on patients with type II diabetes suffering from moderate to severe chronic kidney disease.
LLY vs. NVO: Which Stock Is the Better Value Option? http://www.zacks.com/stock/news/312230/lly-vs-nvo-which-stock-is-the-better-value-option?cid=CS-ZC-FT-312230 Jul 19, 2018 - LLY vs. NVO: Which Stock Is the Better Value Option?
LLY vs. NVO: Which Stock Is the Better Value Option? http://www.zacks.com/stock/news/312246/lly-vs-nvo-which-stock-is-the-better-value-option?cid=CS-ZC--312246 Jul 19, 2018 - LLY vs. NVO: Which Stock Is the Better Value Option?
Top Stocks Set to Disrupt the Diabetes Market https://www.fool.com/investing/2018/07/06/top-stocks-set-to-disrupt-the-diabetes-market.aspx?source=iedfolrf0000001 Jul 06, 2018 - Revolutionary new drugs and medical devices could make these companies smart additions to your portfolio.

Pages: 123456789...16

<<<Page 4>